
|Articles|January 22, 2008
New drug approval addresses two cardiovascular risk factors
Daiichi Sankyo's Welchol, formerly approved to lower LDL-C, has been cleared to reduce blood glucose levels in Type 2 diabetics
Advertisement
Daiichi Sankyo's Welchol (colesevelam HCl) has gained approval for a new indication. It can be used to reduce AIC in adults with Type 2 diabetes. The bile acid sequestrant was approved in 2000 alone or in combination with a statin to reduce elevated LDL-C in patients with primary hypercholesterolemia. The Parsippany, N.J., firm claims the product is the first and only medication approved to lower both glucose levels and low-density lipoprotein cholesterol.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
2
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5







































